1-20 of 47
Hallgeir Rui
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract PO3-13-05: PD-L1 and PD-L2 Protein Expression is Frequently Discordant in Breast Cancer

Lubna Chaudhary, Julie Jorns, Yunguang Sun, Sailaja Kamaraju, Yee Chung Cheng, Amanda Kong, Tina Yen, Caitlin Patten, Chandler Cortina, Inna Chervoneva, Christopher Chitambar, Hallgeir Rui
Journal: Cancer Research
Cancer Res (2024) 84 (9_Supplement): PO3-13-05.
https://doi.org/10.1158/1538-7445.SABCS23-PO3-13-05
Published: 02 May 2024
View article titled, Abstract PO3-13-05: PD-L1 and PD-L2 Protein Expression is Frequently Discordant in Breast Cancer
Journal Articles

Abstract 1634: Cyclin D1 induces Akt1 activity in RB deficient prostate cancer

Xuanmao Jiao, Anthony W. Ashton, Zhiping Li, Ritika Harish, Danni Li, Gordon Robertson, Duanwen Shen, Xiaoming Ju, Ke Chen, Wei Zhang, Samuel Archilefu, Kenneth A. Iczkowski, Hallgeir Rui, Beatrice Knudsen, Paul Timpson, Max Nobis, Richard G. Pestell
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 1634.
https://doi.org/10.1158/1538-7445.AM2024-1634
Published: 22 March 2024
View article titled, Abstract 1634: Cyclin D1 induces Akt1 activity in RB deficient prostate cancer
Journal Articles

Abstract 5534: Needle biopsy induces pro-metastatic progression and systemic dissemination of estrogen receptor-positive breast cancer cells through the COX-2/PGE2 cascade

Hiroyasu Kameyama, Macall Leslie, Reese Simmons, Yunguang Sun, Misung Yi, Priya Dondapati, John F. Langenheim, Kar-Ming Fung, Inna Chervoneva, Hallgeir Rui, Takemi Tanaka
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 5534.
https://doi.org/10.1158/1538-7445.AM2024-5534
Published: 22 March 2024
View article titled, Abstract 5534: Needle biopsy induces pro-metastatic progression and systemic dissemination of estrogen receptor-positive breast cancer cells through the COX-2/PGE<sub>2</sub> cascade
Journal Articles

Abstract 2598: The DACH1 gene is frequently deleted in prostate cancer, restrains prostatic intraepithelial neoplasia, augments DNA damage repair and predicts therapy responses

Zhiping Li, Xuanmao Jiao, Gordon Robertson, Gabriele Di Sante, Anthony W. Ashton, Agnese DiRocco, Min Wang, Jun Zhao, Sankar Addya, Chenguang Wang, Peter A. McCue, Andrew P. South, Carlos Cordon-Cardo, Runzhi Liu, Kishan Patel, Rasha Hamid, Jorim Parmar, James B. DuHadaway, Nikolaus Schultz, Andrew Kossenkov, Lai Yee Phoon, Hao Chen, Li Lan, Yunguang Sun, Kenneth A. Iczkowski, Hallgeir Rui, Richard G. Pestell
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 2598.
https://doi.org/10.1158/1538-7445.AM2023-2598
Published: 04 April 2023
View article titled, Abstract 2598: The <em>DACH1</em> gene is frequently deleted in prostate cancer, restrains prostatic intraepithelial neoplasia, augments DNA damage repair and predicts therapy responses
Journal Articles

Abstract P2-11-13: High PD-L2 Protein Expression in Cancer Cells is an Independent Marker of Unfavorable Prognosis in Luminal Breast Tumors

Lubna N. Chaudhary, Inna Chervoneva, Amy R. Peck, Yunguang Sun, Misung Yi, John F. Langenheim, Julie M. Jorns, Sailaja Kamaraju, Yee Chung Cheng, John Burfeind, Christopher R. Chitambar, Jeffrey A. Hooke, Albert J. Kovatich, Craig Shriver, Hai Hu, Juan P. Palazzo, Marluce Bibbo, Terry Hyslop, Richard Pestell, Edith P. Mitchell, Hallgeir Rui
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): P2-11-13.
https://doi.org/10.1158/1538-7445.SABCS22-P2-11-13
Published: 01 March 2023
View article titled, Abstract P2-11-13: High PD-L2 Protein Expression in Cancer Cells is an Independent Marker of Unfavorable Prognosis in Luminal Breast Tumors
Journal Articles

Abstract OT2-01-02: The SMILE Study: A phase II trial of onapristone in combination with fulvestrant for patients with ER-positive and HER2-negative metastatic breast cancer after progression on endocrine therapy and CDK 4/6 inhibitors

Sailaja Kamaraju, Amy Fowler, Lubna N. Chaudhary, Mark Burkard, Thomas Giever, Robert N Hegeman, Michele Pipp-Dahm, Yee Chung Cheng, Carol Lange, Julie M. Jorns, Amy Stella, Nauman Siddiqui, Luke Zurbriggen, Saurabh Rajguru, Sergey Tarima, Deepika Sriram, Janet Retseck, Hallgeir Rui, Tarek Sahmoud, Kari B. Wisinski
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): OT2-01-02.
https://doi.org/10.1158/1538-7445.SABCS22-OT2-01-02
Published: 01 March 2023
View article titled, Abstract OT2-01-02: The SMILE Study: A phase II trial of onapristone in combination with fulvestrant for patients with ER-positive and HER2-negative metastatic breast cancer after progression on endocrine therapy and CDK 4/6 inhibitors
Journal Articles

Abstract P5-17-08: A phase Ib/II study of leronlimab combined with carboplatin in patients with CCR5+ metastatic triple-negative breast cancer (mTNBC)

Massimo Cristofanilli, Namita Chittoria, Sima Ehsani, Hallgeir Rui, Milana Dolezal, Lisette Stork-Sloots, Femke de Snoo, Christopher Recknor, Vandana Abramson
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): P5-17-08.
https://doi.org/10.1158/1538-7445.SABCS21-P5-17-08
Published: 15 February 2022
View article titled, Abstract P5-17-08: A phase Ib/II study of leronlimab combined with carboplatin in patients with CCR5+ metastatic triple-negative breast cancer (mTNBC)
Journal Articles

Abstract OT2-16-01: The SMILE study: A phase 2 trial of onapristone in combination with fulvestrant for patients with ER+ and HER2- metastatic breast cancer after progression on endocrine therapy and CDK4/6 inhibitors

Sailaja Kamaraju, Amy Fowler, Chung Yee Cheng, Lubna N Chaudhary, John Burfeind, Janet Retseck, Amye J Tevaarwerk, Mark Burkard, Elisavet Paplomata, Amanda M Parkes, Julie M Jorns, Sergey Tarima, Douglas Yee, Hallgeir Rui, Carol Lange, Tarek Sahmoud, Kari B Wisinski
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): OT2-16-01.
https://doi.org/10.1158/1538-7445.SABCS21-OT2-16-01
Published: 15 February 2022
View article titled, Abstract OT2-16-01: The SMILE study: A phase 2 trial of onapristone in combination with fulvestrant for patients with ER+ and HER2- metastatic breast cancer after progression on endocrine therapy and CDK4/6 inhibitors
Journal Articles

Abstract P4-02-03: HER1-4 protein up-regulation following short-term neoadjuvant endocrine therapy in patients with hormone receptor-positive HER2-negative breast cancer

Lubna Naaz Chaudhary, Julie M Jorns, Yee Chung Cheng, Sailaja Kamaraju, John Burfeind, Mary Beth Gonyo, Amanda Kong, Caitlin Patten, Tina Yen, Chandler Cortina, Ebony Carson, Nedra Johnson, Carmen Bergom, Anjishnu Banerjee, Yu Wang, Yunguang Sun, Christopher R Chitambar, Hallgeir Rui
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): P4-02-03.
https://doi.org/10.1158/1538-7445.SABCS21-P4-02-03
Published: 15 February 2022
View article titled, Abstract P4-02-03: HER1-4 protein up-regulation following short-term neoadjuvant endocrine therapy in patients with hormone receptor-positive HER2-negative breast cancer
Journal Articles

Oncostatin M Receptor–Targeted Antibodies Suppress STAT3 Signaling and Inhibit Ovarian Cancer Growth

Anjali Geethadevi, Ajay Nair, Deepak Parashar, Zhiqiang Ku, Wei Xiong, Hui Deng, Yongsheng Li, Jasmine George, Donna M. McAllister, Yunguang Sun, Ishaque P. Kadamberi, Prachi Gupta, Michael B. Dwinell, William H. Bradley, Janet S. Rader, Hallgeir Rui, Robert F. Schwabe, Ningyan Zhang, Sunila Pradeep, Zhiqiang An, Pradeep Chaluvally-Raghavan
Journal: Cancer Research
Cancer Res (2021) 81 (20): 5336–5352.
https://doi.org/10.1158/0008-5472.CAN-21-0483
Published: 15 October 2021
View article titled, Oncostatin M Receptor–Targeted Antibodies Suppress STAT3 Signaling and Inhibit Ovarian Cancer Growth
Open the PDF for Oncostatin M Receptor–Targeted Antibodies Suppress STAT3 Signaling and Inhibit Ovarian Cancer Growth in another window
Includes: Supplementary data
Journal Articles

Abstract PD7-07: Neoadjuvant endocrine therapy helps identify HER2 up-regulation in patients with hormone receptor-positive HER2-negative breast cancer

Lubna N Chaudhary, Julie M Jorns, Yee Chung Cheng, Sailaja Kamaraju, Mary Beth Gonyo, Amanda Kong, Caitlin Patten, Tina Yen, Chandler Cortina, Ebony Carson, Nedra Johnson, Carmen Bergom, Anjishnu Banerjee, Yu Wang, Christopher R Chitambar, Hallgeir Rui
Journal: Cancer Research
Cancer Res (2021) 81 (4_Supplement): PD7-07.
https://doi.org/10.1158/1538-7445.SABCS20-PD7-07
Published: 15 February 2021
View article titled, Abstract PD7-07: Neoadjuvant endocrine therapy helps identify HER2 up-regulation in patients with hormone receptor-positive HER2-negative breast cancer
Journal Articles

Abstract CT233: Phase Ib/II study of leronlimab (PRO 140) combined with carboplatin in CCR5+ mTNBC patients

Massimo Cristofanilli, Milana Dolezal, Jay Lalezari, Hallgeir Rui, Bruce Patterson, Cha-Mei Tang, Daniel Adams, Qiang Zhang, Kazem Kazempour, Nader Pourhassan, Natalie Rabb, Kush Dhody
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): CT233.
https://doi.org/10.1158/1538-7445.AM2020-CT233
Published: 15 August 2020
View article titled, Abstract CT233: Phase Ib/II study of leronlimab (PRO 140) combined with carboplatin in CCR5+ mTNBC patients
Journal Articles

Abstract P2-18-03: Breast cancer treatment and association with clinicopathologic features in TCGA

Jianfang Liu, J. Leigh Fantacone-Campbell, Albert J. Kovatich, Brenda Deyarmin, Bradley J. Mostoller, Jeffrey A. Hooke, Hallgeir Rui, Craig D. Shriver, Hai Hu
Journal: Cancer Research
Cancer Res (2020) 80 (4_Supplement): P2-18-03.
https://doi.org/10.1158/1538-7445.SABCS19-P2-18-03
Published: 15 February 2020
View article titled, Abstract P2-18-03: Breast cancer treatment and association with clinicopathologic features in TCGA
Journal Articles

Abstract PD4-04: Leronlimab, a humanized monoclonal antibody to CCR5, restrains breast cancer metastasis and enhances cell death induced by DNA damaging chemotherapies

Richard G Pestell, Massimo Cristofanilli, Hallgeir Rui, Xuanmao Jiao, Min Wang
Journal: Cancer Research
Cancer Res (2020) 80 (4_Supplement): PD4-04.
https://doi.org/10.1158/1538-7445.SABCS19-PD4-04
Published: 15 February 2020
View article titled, Abstract PD4-04: Leronlimab, a humanized monoclonal antibody to CCR5, restrains breast cancer metastasis and enhances cell death induced by DNA damaging chemotherapies
Journal Articles

Abstract P6-04-23: HER2 up-regulation with neoadjuvant endocrine therapy in patients with hormone receptor-positive, HER2-negative breast cancer

Lubna N Chaudhary, Julie Jorns, MaryBeth Gonyo, Amanda Kong, Amy R Peck, Yunguang Sun, Carmen Bergom, Anjishnu Banarjee, Christopher Chitambar, Hallgeir Rui
Journal: Cancer Research
Cancer Res (2020) 80 (4_Supplement): P6-04-23.
https://doi.org/10.1158/1538-7445.SABCS19-P6-04-23
Published: 15 February 2020
View article titled, Abstract P6-04-23: HER2 up-regulation with neoadjuvant endocrine therapy in patients with hormone receptor-positive, HER2-negative breast cancer
Journal Articles

Abstract 408: Evidence of DLL4, NNAT, and SLC35C2 in suppression of breast cancer initiation, growth, and metastasis

Cody Plasterer, Angela Lemke, Dana Murphy, Carmen Bergom, Amit Joshi, Hallgeir Rui, Michael J. Flister
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 408.
https://doi.org/10.1158/1538-7445.AM2018-408
Published: 01 July 2018
View article titled, Abstract 408: Evidence of DLL4, NNAT, and SLC35C2 in suppression of breast cancer initiation, growth, and metastasis
Journal Articles

CCR5 Governs DNA Damage Repair and Breast Cancer Stem Cell Expansion

Xuanmao Jiao, Marco A. Velasco-Velázquez, Min Wang, Zhiping Li, Hallgeir Rui, Amy R. Peck, James E. Korkola, Xuelian Chen, Shaohua Xu, James B. DuHadaway, Sandra Guerrero-Rodriguez, Sankar Addya, Daniela Sicoli, Zhaomei Mu, Gang Zhang, Andres Stucky, Xi Zhang, Massimo Cristofanilli, Alessandro Fatatis, Joe W. Gray, Jiang F. Zhong, George C. Prendergast, Richard G. Pestell
Journal: Cancer Research
Cancer Res (2018) 78 (7): 1657–1671.
https://doi.org/10.1158/0008-5472.CAN-17-0915
Published: 01 April 2018
View article titled, CCR5 Governs DNA Damage Repair and Breast Cancer Stem Cell Expansion
Open the PDF for CCR5 Governs DNA Damage Repair and Breast Cancer Stem Cell Expansion in another window
Includes: Supplementary data
Journal Articles

Abstract A19: CCR5 contributes to breast cancer stem cell expansion by enhancing DNA damage repair

Xuanmao Jiao, Marco Velasco, Zhiping Li, Shaohua Xu, Massimo Cristofanilli, Hallgeir Rui, Richard G. Pestell
Journal: Cancer Research
Cancer Res (2016) 76 (3_Supplement): A19.
https://doi.org/10.1158/1538-7445.FBCR15-A19
Published: 07 April 2016
View article titled, Abstract A19: CCR5 contributes to breast cancer stem cell expansion by enhancing DNA damage repair
Journal Articles

Abstract 1281: Serum levels of the immunomodulatory protein, the progesterone induced blocking factor (PIBF) are not higher in women with progesterone (P) receptor (R) positive vs. negative breast cancer

Jerome H. Check, Anne Rosenberg, Ann DiAntonio, Hallgeir Rui, Rachael Cohen, Gabrielle DiAntonio
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): 1281.
https://doi.org/10.1158/1538-7445.AM2015-1281
Published: 01 August 2015
View article titled, Abstract 1281: Serum levels of the immunomodulatory protein, the progesterone induced blocking factor (PIBF) are not higher in women with progesterone (P) receptor (R) positive vs. negative breast cancer
Journal Articles

Abstract 5295: Latent class longitudinal modeling of CTCs in ER+ metastatic breast cancer patients

Terry Hyslop, Xuechan Li, Rui Duan, Mario Giuliano, Antonio Giordano, Marlana Orloff, Hallgeir Rui, James M. Reuben, Massimo Cristofanilli
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): 5295.
https://doi.org/10.1158/1538-7445.AM2015-5295
Published: 01 August 2015
View article titled, Abstract 5295: Latent class longitudinal modeling of CTCs in ER+ metastatic breast cancer patients